<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-14T11:09:49Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/68b69jjx7p.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/68b69jjx7p.1</identifier>
                <datestamp>2020-02-11T14:20:11Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>agostoni, piergiuseppe</dc:creator>
    <dc:title>Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. </dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>Background: Hyperuricemia prognostic impact on clinical outcomes in chronic heart failure (HF) patients has been investigated with inconclusive results. 
Objectives: Aim of the study was to evaluate the prognostic impact of serum uric acid (SUA) on long-term clinical outcomes in HF.
Methods: An analysis of MECKI (Metabolic Exercise Cardiac Kidney Index) database, with median follow-up of 3.4 years. 
Results: Relation between SUA  and all-cause/ cardiovascular (CV) deaths have been analysed in 4,577 patients (3,688 males, age 62.7±12.9 years), with reduced ejection fraction HF ( 35±11%), peakVO2 1151±440 ml/min; NYHA class I-II (72.6%),  III-IV (27.4%). SUA was associated with increased total and CV mortality (HR 1.120 and HR 1.128, respectively p&lt;0.0001), also after adjustment for peakVO2, VE/VCO2 slope, diuretic use and MECKI score.  SUA was significantly associated with CV mortality only in NYHA class I-II (HR 1.17, p&lt;0.0001) while there was no association in class III-IV (HR 1.03, p=NS).  No prognostic added values of SUA with respect to the MECKI score was observed at the ROC analysis. 
Conclusions: SUA is confirmed to be associated with increased mortality, but in less severe HF only. However SUA did not show additional prognostic power to the MECKI score 
</dc:description>
    <dc:subject>Heart Failure</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/68b69jjx7p.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/68b69jjx7p.1</dc:identifier>
    <dc:rights>Attribution-NonCommercial 3.0 Unported</dc:rights>
    <dc:rights>https://creativecommons.org/licenses/by-nc/3.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/68b69jjx7p</dc:relation>
    <dc:date>2020-02-11T14:20:11Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
